SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal fourth-quarter report is the dominant focus, with traders watching whether AI-driven memory demand, tight DRAM and NAND supply, and pricing strength will support a strong outlook. Many expect a strong report, but others warn that high expectations may be priced in and debate whether the memory cycle can last, raising the possibility of a sell-the-news reaction.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for Amtagvi and Proleukin, is driving a sharp rally and analyst upgrades. Traders are debating whether heavy volume reflects short covering or sustainable commercial progress, while many bullish posts point to upcoming lung-cancer data and other pipeline catalysts; others warn of profit-taking and possible dilution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors presentation of 24-month HOPE-3 open-label extension data for deramiocel at the World Muscle Society congress is the main focus, with traders watching delayed-start and natural-history analyses for evidence of sustained benefit ahead of the FDAs November review decision. Bulls view the data as support for approval, while skeptics emphasize that open-label results may not resolve the FDAs concerns over the trials statistical analysis plan and efficacy evidence.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A prolonged selloff to multiyear lows is drawing attention amid concerns about slowing growth, weak advertising demand and competition from Amazon and other platforms. Traders are split between seeing the cash-rich, profitable business as undervalued and expecting further declines unless management restores growth; speculation about an Apple Safari issue is disputed.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Traders are focusing on reports that Boeing won the U.S. Navys next-generation fighter contract, with some attributing an after-hours bounce to the award. Others remain cautious, pointing to the 737 MAX 10 certification delay and labor uncertainty as ongoing risks.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Traders are focused on the pause in the marijuana rescheduling hearing while the judge considers whether to add a GAO report on federal drug-scheduling procedures to the record, delaying the awaited Schedule III recommendation. The delay has fueled frustration and selling, while bulls argue it is proceduralnot a decision against reschedulingand view the pullback as an opportunity.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs move to place VantageScore alongside FICO on Fannie Mae and Freddie Mac mortgage pricing gridsand lenders adoption of the alternative modelhas raised concerns that competition could erode FICOs mortgage-scoring dominance and pricing power, driving a sharp selloff. Traders disagree over whether the market is overreacting given the companys continued growth and entrenched business, or whether the change marks a lasting weakening of its moat.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Cannabis rescheduling is the dominant focus, with traders reacting to a pause in the DEA hearing process while the judge considers whether to reopen the record for a GAO report. Many view it as a delay rather than a setback and remain optimistic about eventual Schedule III treatment and tax relief, while others are frustrated by the uncertain timeline.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths planned Nasdaq listing through the Armada SPAC merger and its proposed XRP treasury are driving attention, with traders reacting to the shareholder vote, registration progress and sharp, halt-prone trading. Bullish posts frame XRPN and its warrants as leveraged exposure to XRP, while others question the merger outcome, valuation and SPAC risk.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

A sharp rebound from a recent 52-week low on elevated volume has fueled short-squeeze speculation. Bulls also cite potential margin improvement as U.S. manufacturing ramps, while skeptics point to recent losses and weak solar-sector conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbCellera is drawing attention after positive Phase 2 results for ABCL635, its investigational treatment for menopausal hot flashes, and ahead of a scheduled presentation of further trial data at the IMS World Congress on Menopause. Traders are broadly bullish on the clinical progress and recent share momentum, while some caution that the drug still faces further testing and debate whether the move can continue.

The move appears tied to attention around ABCL635s Phase 2 menopause data and its planned presentation at the IMS World Congress. Traders also cite JPMorgans reported Overweight initiation with a $17 price target.

Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Ocenico Hotel and Congress Center in Rio de Janeiro, Brazil...

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through...

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals' FDA approval and the companies' antibody partnership.read more...

Monday 8/17 Insider Buying Report: ABCL, BPRN

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At AbCellera Biologics, a filing with the SEC revealed that on Wednesday, Director...

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to...

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.read more...

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.read more...

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

Equity

Extremely Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCL AbCellera Biologics Inc

Fundamentals

Latest ABCL News